Quantbot Technologies LP bought a new position in GlaxoSmithKline PLC (NYSE:GSK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 127,963 shares of the pharmaceutical company’s stock, valued at approximately $5,517,000.

Several other large investors have also recently made changes to their positions in the company. Woodley Farra Manion Portfolio Management Inc. raised its position in shares of GlaxoSmithKline PLC by 1.7% in the 2nd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 95,759 shares of the pharmaceutical company’s stock worth $4,129,000 after acquiring an additional 1,640 shares in the last quarter. MML Investors Services LLC raised its position in shares of GlaxoSmithKline PLC by 6.8% in the 2nd quarter. MML Investors Services LLC now owns 84,162 shares of the pharmaceutical company’s stock worth $3,629,000 after acquiring an additional 5,342 shares in the last quarter. TIAA FSB bought a new position in shares of GlaxoSmithKline PLC in the 2nd quarter worth approximately $1,517,000. ETRADE Capital Management LLC raised its position in shares of GlaxoSmithKline PLC by 11.0% in the 2nd quarter. ETRADE Capital Management LLC now owns 105,406 shares of the pharmaceutical company’s stock worth $4,545,000 after acquiring an additional 10,431 shares in the last quarter. Finally, FMR LLC raised its position in shares of GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares in the last quarter. 9.28% of the stock is owned by hedge funds and other institutional investors.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded up 0.65% during mid-day trading on Thursday, reaching $40.44. The company’s stock had a trading volume of 3,026,509 shares. The firm’s 50 day moving average is $39.76 and its 200 day moving average is $41.75. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54. The firm has a market cap of $98.84 billion, a PE ratio of 39.96 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The company had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities analysts anticipate that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be issued a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.89%. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is currently 197.00%.

Several research analysts have recently issued reports on the company. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday. Citigroup Inc. downgraded GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. BidaskClub downgraded GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. Finally, TheStreet downgraded GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and a consensus target price of $44.67.

TRADEMARK VIOLATION NOTICE: “Quantbot Technologies LP Buys Shares of 127,963 GlaxoSmithKline PLC (GSK)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/quantbot-technologies-lp-buys-shares-of-127963-glaxosmithkline-plc-gsk/1578464.html.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.